@FiercePharma: Funnily enough, we publish Top 15 Drug Launch Superstars, and 1000s click thru to last year's Top 10 Launch Disasters. | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Acino agrees to $439M takeover offer from private equity firms. More | Follow @CarlyHFierce
> On the heels of regulatory approval for its takeover by Actavis ($ACT), Warner Chilcott said it would lay off 88 workers from a New Jersey facility. Report
> The U.K.'s cost-effectiveness watchdog is reconsidering its previous position against Roche's ($RHHBY) MabThera as a treatment for a rare autoimmune disorder. Report
> GlaxoSmithKline ($GSK) said it would invest €2.2 million in Greece to boost packaging capacity for four over-the-counter products. Report
> Forest Laboratories ($FRX) filed another lawsuit against First Time US Generics over the latter's plans to sell a copy of the drugmaker's product Savella. Report
> Three death row inmates sued the state of Texas, claiming that officials plan to experiment with new execution drugs that they obtained from drugmakers under false pretenses. Report
@FierceMedDev: Lensar hauls in $87M for laser eye surgery tech. News | Follow @FierceMedDev
@MarkHFierce: FierceDiagnostics has another great crop of stories for you. Check it out | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Oral peptide delivery biz Enteris lands Nordic partnership. More from FierceDrugDelivery | Follow @MichaelGFierce
> Covidien CEO: It's about how, not how much, you spend on R&D. Report
> With Mako set for sale, Wright may be next orthopedic M&A target. Story
> Report: French regulators acted too slowly on PIP breast implant scandal. Item
Biotech News
@FierceBiotech: ICYMI: Top 15 highest paid biopharma R&D chiefs. Special report | Follow @FierceBiotech
@JohnCFierce: The turnaround plan: stay put, target drugs, more deals--John Reed sets out on a long-distance run at Roche's pRED. Feature | Follow @JohnCFierce
@DamianFierce: Updated story on Frazier's $377M new fund with comments from General Partner Jamie Topper. ICYMI yesterday | Follow @DamianFierce
@EmilyMFierce: NIH Feels Multiplying Effects of Government Shutdown. Article from Scientific American | Follow @EmilyMFierce
> Analyst: More Lilly R&D failures likely to trigger 'savage cost cuts.' More
> Cancer biotech upstart nabs $33M A round for R&D work, Array collaboration. Story
> J&J makes an R&D splash with $42M venture play, biotech collaborations. Report
> Shutdown halts NIH drug trials as researchers hit brakes on preclinical research. Article
Vaccines News
> NIH expands vaccine clinical trial network. Item
> CDC reports across-the-board rises in flu vaccine uptake. Report
> Researchers highlight knowledge gaps hindering cancer vaccines. Story
> Vaccines spared as Merck takes ax to R&D. More
> Government shutdown forces CDC to halt seasonal flu program. Article
Pharma Manufacturing News
@EricPFierce: Hospira faces more vial problems. FDA and co. says glass strands pose potential health threat. More | Follow @EricPFierce
> Ranbaxy denies FDA issues will lead to layoffs. Item
> SCM offers 'blank canvas' to sterile injectable clients. Story
> FDA threatens drugmaker with ban for not paying user fee. Article
> CML, AAIPharma join forces to create CMC specialist. More
And Finally... Belgium's UCB backed a U.K.government plan to invest £400 million into science and engineering training at English universities, but it asked for more innovation-friendly moves. Report
